Autopsy report · NCT02521233

Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“Sponsor decision”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 3
Sponsor: EMS
Sponsor type: Industry
Conditions: Essential Arterial Hypertension
Interventions: Candesartan + Chlorthalidone (8mg+12,5mg); Candesartan + Chlorthalidone (8 mg + 25 mg); losartan+hydrochlorothiazide
Participants: 0

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.